Inve India ▾

Vaidya Sane Ayurved Laboratories share price & results

Vaidya Sane Ayurved Laboratories Ltd· Healthcare

Results to
Mar 2026
Latest analysed call
Q2 FY26
Ownership as of
Mar 2026

Ayurvedic chronic-care chain running Madhavbaug clinics and hospitals for heart-disease, diabetes, BP and obesity reversal, with in-house manufacturing of Ayurvedic medicines and diet kits

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue57.0 ₹ crore+18.8% YoYQuarterly, as filedQuarter to Mar 2026Revenue from operations as filed.
Operating margin12.0 %−6.0 pts YoYOperating profit / revenueQuarter to Mar 2026For the quarter; a change is in percentage points.
Net profit4.0 ₹ crore+33.3% YoYQuarterly, as filedQuarter to Mar 2026Profit after tax as filed.
Return on equityUnavailable−1.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.
Free cash flow margin-2.69 %−5.5 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)Unavailable+28.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Mar 2026

Guidance

What management said, and what became of it

0 of 1 judged target kept · 7 open · verdicts reflect calls analysed to Q2 FY26.

Vaidya Sane Ayurved Laboratories Ltd management guidance track record on Inve: 8 targets tracked across analysed earnings calls (0 achieved, 1 missed, 7 open).

TargetOriginal wordingSaidLatest callVerdict
GIPSA Approval Statuswithin a couple of months max, we should be GIPSA approved
Call transcript, Q4 FY25 · 23 May 2025		Q4 FY25Q2 FY26:No mention of GIPSA approval in the provided text.
Call transcript, Q2 FY26 · 7 Nov 2025		Ghosted
FY26 EBITDA Marginreach about 16% or so
Call transcript, Q4 FY25 · 23 May 2025		Q4 FY25Q2 FY26:Targeting an EBITDA margin of around 17% to 18%
Call transcript, Q2 FY26 · 7 Nov 2025		Revised Up
FY26 RevenueRs. 110 to Rs. 120 crore kind of revenue next year
Call transcript, Q4 FY25 · 23 May 2025		Q4 FY25Q2 FY26:Expect revenue to cross about INR 115 crores to INR 120 crores
Call transcript, Q2 FY26 · 7 Nov 2025		On Track

Source: Inve Guidance Tracker for Vaidya Sane Ayurved Laboratories Ltd · to Q2 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of Vaidya Sane Ayurved Laboratories Ltd's 8 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 5 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹146.45 0.00% · ₹0

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −44.8% 1Y

₹150₹200₹250Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 7 Nov 2025

1Y: ₹265.5 on 24 Oct 2025 → ₹146.45. High ₹287.95 (29 Dec 2025), low ₹146.45 (22 Oct 2026).

Previous close
₹146.45
Market cap
₹182 Cr
52-week range
₹146.45 – ₹287.95
One year
−46.16%
Price to earnings (FY ending Mar 2026)
20.22×
Return on equity (FY ending Mar 2026)
11.92%

Overview

Symbol
NSE:MADHAVBAUG
Exchange
NSE
Currency
INR

What Vaidya Sane Ayurved Laboratories Ltd does

Based on the company's own presentations, annual report and earnings calls.

Vaidya Sane Ayurved Laboratories operates under the 'Madhavbaug' brand, delivering non-invasive disease-reversal treatment through a network of clinics and hospitals that combine Ayurveda with modern diagnostics, diet management and physiotherapy for cardiac disease, diabetes, hypertension and obesity. Its subsidiaries Dynamic Remedies and UV Ayurgen Pharma manufacture the Ayurvedic medicines, nutraceuticals and standardized diet kits used across the clinic and hospital network. The company also runs a digital ecosystem (MIB Pulse app and Power MAP analytics) for patient monitoring, and has begun international expansion via a joint venture in Malaysia and a new neuro-care vertical (Urja Neuro Care).

Segments

  • Clinics
  • Hospitals
  • Products
Clinics network
320+ clinics across 14 states & UTs
Operational hospitals
4 (Khopoli, Kondhali/Nagpur, Vizag, Vadodara)
Total hospital beds
134 (Khopoli 45, Vadodara 35, Kondhali 30, Vizag 24)
Rural reach
46+ OPDs and mini clinics
Ayurveda physicians
450+
Patients treated (cumulative)
Over 10 lakh
Founded 2006Headquarters Pune, Maharashtra Company website

How the price took the results

close before → close after

Q2 FY26
+6.1%
7 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Vaidya Sane Ayurved Laboratories Ltd

Free account: one company. Everything above stays public.

Write why you follow Vaidya Sane Ayurved Laboratories Ltd and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Vaidya Sane Ayurved Laboratories Ltd

Guides on how to read this kind of business and the numbers that matter.